Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Biliary Tract Neoplasms
  • Deoxycytidine
  • Enzyme Inhibitors
  • Pyridines
  • Ribonucleotide Reductases
  • Thiosemicarbazones

abstract

  • Despite evidence for RR inhibition in vivo, the 3-AP plus gemcitabine combination is not likely to be associated with a response rate exceeding 30% in patients with adenocarcinoma of the biliary tract.

publication date

  • August 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3446256

Digital Object Identifier (DOI)

  • 10.1007/s00280-010-1481-z

PubMed ID

  • 20981545

Additional Document Info

start page

  • 379

end page

  • 88

volume

  • 68

number

  • 2